Compare 8 eCOA platforms by their documented instrument support, compliance, multilingual use, capture modes, setup and pricing basis. WeGuide is included for clinical trials and research studies that connect electronic assessments with ongoing participant engagement and follow-up. Each feature links to its public source.
Best forSponsors, CROs and academic research teams choosing an eCOA platform for a regulated clinical trial.
Updated Nov 13, 20268 tools compared
eCOA
What is eCOA software?
eCOA stands for electronic clinical outcome assessment. It is software for recording how participants feel or function through patient questionnaires, clinician or caregiver observations, and structured performance tasks. ePRO is the patient-reported part of this broader category.
See documented feature support at a glance. Select a symbol for the explanation and source. Double checks indicate documented extra capabilities; unknown does not mean unavailable.
Products are not ranked. Table order is chosen for each guide and does not indicate a recommendation.
Columns 6 of 6
Feature 1 of 6
Select a symbol to read its evidence and source. Scroll sideways for all features.
Documented feature support for each product. Symbols describe individual features, not overall product ratings.
A reusable instrument library is paired with a validated instrument license-management service.
Extended support means: A validated or instrument-author-approved library plus managed instrument licensing are documented.
2,500+ COAs and a global instrument library for reusing builds and translations; Medidata also offers a validated instrument license management service.
Part 11, Annex 11 and ICH E6 statements are documented; the approval claim is company-wide.
Supported means: Relevant trial or security controls are stated.
Medidata says its AI functionality supports 80% of 2025 FDA novel drug approvals (company-wide platform claim, not eCOA alone); position statements on Part 11, Annex 11 and ICH E6 are published.
Study builders configure questionnaires in Designer, with an average eight-week study start.
Extended support means: Study teams can configure the study themselves, with a stated build or launch timeframe.
Medidata Designer lets study builders configure questionnaires with drag-and-drop templates; average study start 8 weeks versus a 12-week industry standard.
Supported means: A production pricing basis, model or contract terms beyond a sales contact are published.
No prices published; Medidata's public Patient Cloud service descriptions set out contract terms, such as devices provisioned on a rental basis, caps on fee adjustments and early-termination fees.
Validated instruments are available, with licensing and validation managed by Professional Services.
Extended support means: A validated or instrument-author-approved library plus managed instrument licensing are documented.
Library of validated instruments (EORTC, FACT-G, EQ-5D, SF-36, PROMIS); Professional Services manages scale licensing and validation; library size not published.
App, web and EDC connections are documented; wearable or sensor capture is not.
Supported means: Electronic outcome capture and a connection to another trial system or device are documented.
BYOD app, browser, SMS and messaging apps, site tablet mode and provisioned devices; integrates with major EDCs via REST API and webhooks. Wearable or sensor capture not documented.
Supported means: A production pricing basis, model or contract terms beyond a sales contact are published.
Pricing process published: itemized, fixed-scope proposal with change-control terms within 5 business days, plus a Castor Essentials package for early-stage companies; no prices.
ISO/SOC certifications are stated; this note does not establish a public certificate or audit report.
Supported means: Relevant trial or security controls are stated.
States it has supported 70% of FDA and EMA new drug approvals since 2015 (company-wide, all endpoint types); ISO 27001:2022 and SOC 2 Type II are published separately.
Vendor-delivered oncology deployment timing is stated; a self-service designer is not documented.
Supported means: A study build process, self-service builder or launch timeframe is documented.
eCOA Swift deploys early-phase oncology trials in as little as 2 weeks and Rapid Start offers pre-configured assessments; builds are vendor-delivered, no self-service designer published.
Outcome forms and licensing support are described; confirm author approval and the managed licensing scope for each selected instrument before assuming the extended definition is met.
Supported means: A library of outcome-assessment instruments is documented.
WeGuide publishes an assessment-instrument library and describes instrument licensing and digital-migration support. Confirm permissions and validation responsibilities for each chosen instrument.
Public statements establish the documented-support level; no public certificate or audit report establishes extended support.
Supported means: Relevant trial or security controls are stated.
WeGuide states ISO 27001:2022 certification and support for GDPR, HIPAA and 21 CFR Part 11. The public material does not provide the certificate or an audit report.
Published multicountry research and multilingual participant workflows meet the shared definition.
Extended support means: Both multicountry use and multilingual/localized participant support are documented.
WeGuide describes BRACE across five countries and INHERIT in ten languages. These are examples of participant outcome collection, rather than a claim of enterprise-scale eCOA deployment.
Electronic capture and system connections are documented; the source does not establish provisioned-device fleet support.
Supported means: Electronic outcome capture and a connection to another trial system or device are documented.
Electronic participant outcome forms connect to existing EDC systems through the Integration Engine. Provisioned-device fleet delivery is not established by this source.
The questionnaire library is paired with licensing and validation handled by language-service partners.
Extended support means: A validated or instrument-author-approved library plus managed instrument licensing are documented.
Questionnaire library and translation tools built with linguistic validation agencies; licensing and validation handled with language-service partners.
A validated library is documented; licensing services are not described.
Supported means: A library of outcome-assessment instruments is documented.
400+ pre-built, validated instruments in a reusable library with AI-assisted instrument generation; licensing services are not described on the pages checked.
Supported means: Relevant trial or security controls are stated.
States compliance with 21 CFR Part 11, Annex 11, HIPAA, GDPR and ICH GCP and says its eCOA data can support primary endpoints in pivotal studies; deployed in nearly 400 trials, with no approval counts published.
Every product uses the same definitions. Double checks indicate documented extra capabilities in that column; they do not indicate an overall winner. Unknown means the available sources do not establish support.
Validated instrument library and licensing
Supported: A library of outcome-assessment instruments is documented.
Extended support: A validated or instrument-author-approved library plus managed instrument licensing are documented.
Regulatory compliance and track record
Supported: Relevant trial or security controls are stated.
Extended support: Relevant trial controls plus a public ISO/SOC certificate or audit report are documented; a certification claim or logo alone is insufficient.
Global scale and languages
Supported: Multicountry use or multilingual/localized participant support is documented.
Extended support: Both multicountry use and multilingual/localized participant support are documented.
Capture modes and integrations
Supported: Electronic outcome capture and a connection to another trial system or device are documented.
Extended support: Capture on participant-owned and provisioned devices plus wearable or sensor integration are documented.
Time to launch and self-service build
Supported: A study build process, self-service builder or launch timeframe is documented.
Extended support: Study teams can configure the study themselves, with a stated build or launch timeframe.
Published pricing and terms
Supported: A production pricing basis, model or contract terms beyond a sales contact are published.
Extended support: Numerical production prices or a free production option with its conditions are published.
Read the detailed feature comparison
Columns 6 of 6
Feature 1 of 6
Select a feature label for its details and source. Scroll sideways for all features.
Feature statements for each product, with public sources. Products appear in editorial order.
2,500+ COAs + license management — details and source
2,500+ COAs and a global instrument library for reusing builds and translations; Medidata also offers a validated instrument license management service.
Part 11, Annex 11 + ICH E6 statements — details and source
Medidata says its AI functionality supports 80% of 2025 FDA novel drug approvals (company-wide platform claim, not eCOA alone); position statements on Part 11, Annex 11 and ICH E6 are published.
Designer; average 8-week start (vendor claim) — details and source
Medidata Designer lets study builders configure questionnaires with drag-and-drop templates; average study start 8 weeks versus a 12-week industry standard.
Prices unpublished; rental and contract terms public — details and source
No prices published; Medidata's public Patient Cloud service descriptions set out contract terms, such as devices provisioned on a rental basis, caps on fee adjustments and early-termination fees.
Validated library + managed licensing — details and source
Library of validated instruments (EORTC, FACT-G, EQ-5D, SF-36, PROMIS); Professional Services manages scale licensing and validation; library size not published.
App, web + SMS; wearables not documented — details and source
BYOD app, browser, SMS and messaging apps, site tablet mode and provisioned devices; integrates with major EDCs via REST API and webhooks. Wearable or sensor capture not documented.
Fixed-scope quotes; prices not published — details and source
Pricing process published: itemized, fixed-scope proposal with change-control terms within 5 business days, plus a Castor Essentials package for early-stage companies; no prices.
ISO 27001 + SOC 2 Type II stated — details and source
States it has supported 70% of FDA and EMA new drug approvals since 2015 (company-wide, all endpoint types); ISO 27001:2022 and SOC 2 Type II are published separately.
From 2 weeks for early oncology (vendor claim) — details and source
eCOA Swift deploys early-phase oncology trials in as little as 2 weeks and Rapid Start offers pre-configured assessments; builds are vendor-delivered, no self-service designer published.
Instrument library and licensing support — details and source
WeGuide publishes an assessment-instrument library and describes instrument licensing and digital-migration support. Confirm permissions and validation responsibilities for each chosen instrument.
Trial/privacy controls and ISO certification stated — details and source
WeGuide states ISO 27001:2022 certification and support for GDPR, HIPAA and 21 CFR Part 11. The public material does not provide the certificate or an audit report.
BRACE in five countries; multilingual studies — details and source
WeGuide describes BRACE across five countries and INHERIT in ten languages. These are examples of participant outcome collection, rather than a claim of enterprise-scale eCOA deployment.
Participant app, forms and EDC/device connections — details and source
Electronic participant outcome forms connect to existing EDC systems through the Integration Engine. Provisioned-device fleet delivery is not established by this source.
Questionnaire library + licensing partners — details and source
Questionnaire library and translation tools built with linguistic validation agencies; licensing and validation handled with language-service partners.
400+ instruments; licensing services not described — details and source
400+ pre-built, validated instruments in a reusable library with AI-assisted instrument generation; licensing services are not described on the pages checked.
Part 11/Annex 11 stated; no approval counts — details and source
States compliance with 21 CFR Part 11, Annex 11, HIPAA, GDPR and ICH GCP and says its eCOA data can support primary endpoints in pivotal studies; deployed in nearly 400 trials, with no approval counts published.
Medidata eCOAStudy fit: large sponsors and CROs that already run Rave EDC and want eCOA in the same platform
CastorStudy fit: biotech, device and academic teams that want eCOA, eConsent and EDC in one platform with a self-service option
ClarioStudy fit: global pivotal trials that combine eCOA with cardiac, respiratory, imaging or sensor endpoints
WeGuideStudy fit: clinical trials and research studies where ongoing participant engagement is central, with electronic assessments, reminders and follow-up in one study app
KayentisStudy fit: phase II-III sponsors that want a specialist eCOA vendor with site and patient helpdesk support
MedableStudy fit: sponsors and CROs that want a no-code eCOA build tool with eConsent and televisits on one platform
Signant eCOAStudy fit: CNS and other complex-endpoint trials that need clinician ratings, licensing support and global logistics
YPrimeStudy fit: sponsors that want eCOA, IRT and eConsent from one vendor across many languages
No prices published; the Patient Cloud service descriptions publish contract terms (devices on a rental basis, caps on fee adjustments, early-termination fees)
Native Garmin integration; Apple Health and Health Connect data routes; Fitbit Air support is listed. For other devices, available data depends on what their apps share with the phone health store.
Study fit: large sponsors and CROs that already run Rave EDC and want eCOA in the same platform
Medidata eCOA lists 2,500+ COAs, 200+ languages and dialects and 1,600+ studies, and data flows straight into Rave EDC. Study builders can configure it in Medidata Designer, with an average study start of 8 weeks. Prices are not published.
Validated instrument library and licensing
2,500+ COAs and a global instrument library for reusing builds and translations; Medidata also offers a validated instrument license management service.
Medidata says its AI functionality supports 80% of 2025 FDA novel drug approvals (company-wide platform claim, not eCOA alone); position statements on Part 11, Annex 11 and ICH E6 are published.
Medidata Designer lets study builders configure questionnaires with drag-and-drop templates; average study start 8 weeks versus a 12-week industry standard.
No prices published; Medidata's public Patient Cloud service descriptions set out contract terms, such as devices provisioned on a rental basis, caps on fee adjustments and early-termination fees.
No prices published; the Patient Cloud service descriptions publish contract terms (devices on a rental basis, caps on fee adjustments, early-termination fees)Source
Security certifications
ISO 27001:2022, ISO 27017:2015, ISO 27018:2019, ISO 27701:2019, SOC 2+ Type IISource
Headquarters
New York, NY (350 Hudson Street, per ISO certificate)Source
Less suitable for teams that need published prices or a self-serve contract for a single small study.
Study fit: biotech, device and academic teams that want eCOA, eConsent and EDC in one platform with a self-service option
Castor offers a validated instrument library with licensing handled by its services team, self-service builds that go live in weeks and a published pricing process with an entry package for early-stage companies. Its global reach and regulatory track record are smaller than the enterprise platforms'.
Validated instrument library and licensing
Library of validated instruments (EORTC, FACT-G, EQ-5D, SF-36, PROMIS); Professional Services manages scale licensing and validation; library size not published.
BYOD app, browser, SMS and messaging apps, site tablet mode and provisioned devices; integrates with major EDCs via REST API and webhooks. Wearable or sensor capture not documented.
Pricing process published: itemized, fixed-scope proposal with change-control terms within 5 business days, plus a Castor Essentials package for early-stage companies; no prices.
Study fit: global pivotal trials that combine eCOA with cardiac, respiratory, imaging or sensor endpoints
Clario has the deepest enterprise eCOA profile here: studies in 120+ countries and 100+ languages, a named eCOA science team and pre-validated assessment libraries. It says it has supported 70% of FDA and EMA new drug approvals since 2015 across its endpoints. Builds are delivered by Clario and prices are not published.
Validated instrument library and licensing
Pre-built, validated assessment libraries, the Rapid Start assessment catalog and an eCOA Science Services team with named scientists.
States it has supported 70% of FDA and EMA new drug approvals since 2015 (company-wide, all endpoint types); ISO 27001:2022 and SOC 2 Type II are published separately.
eCOA Swift deploys early-phase oncology trials in as little as 2 weeks and Rapid Start offers pre-configured assessments; builds are vendor-delivered, no self-service designer published.
Study fit: clinical trials and research studies where ongoing participant engagement is central, with electronic assessments, reminders and follow-up in one study app
WeGuide combines electronic outcome assessments with ongoing participant engagement for clinical trials and research studies. Teams connect assessments with consent, reminders and follow-up in a branded study app, with multilingual and wearable-data options. This supports study designs that need participants to stay involved between visits or over time, including investigator-led studies, cohorts and registries. Suitability depends on the assessments and workflows required, rather than study size alone. Confirm instrument licensing, assessment validation and any intensive site-entry or device-logistics needs.
Validated instrument library and licensing
WeGuide publishes an assessment-instrument library and describes instrument licensing and digital-migration support. Confirm permissions and validation responsibilities for each chosen instrument.
WeGuide states ISO 27001:2022 certification and support for GDPR, HIPAA and 21 CFR Part 11. The public material does not provide the certificate or an audit report.
WeGuide describes BRACE across five countries and INHERIT in ten languages. These are examples of participant outcome collection, rather than a claim of enterprise-scale eCOA deployment.
Electronic participant outcome forms connect to existing EDC systems through the Integration Engine. Provisioned-device fleet delivery is not established by this source.
Quoted per study, with hosting, support and modules included. Email hello@weguide.health for a study-specific quote; price amounts are not published.Source
Compliance claims
Supports 21 CFR Part 11 requirements (stated); EU Annex 11 not statedSource
Compliance claims
WeGuide states 21 CFR Part 11 and HIPAA support; confirm the study-specific validation scope and BAA requirements.Source
Security certifications
ISO 27001:2022 (stated; certificate not published); no SOC 2 claim foundSource
Less suitable for protocols requiring a fully managed global provisioned-device fleet or an enterprise EDC and drug-supply suite from the same provider; confirm the required capture modes and services.
Study fit: phase II-III sponsors that want a specialist eCOA vendor with site and patient helpdesk support
Kayentis is an eCOA specialist with 280+ trials in 85 countries and 120 languages, and its Clin'form app runs on BYOD, provisioned devices, web and interview mode. It does not publish build timelines, approval counts or prices.
Validated instrument library and licensing
Questionnaire library and translation tools built with linguistic validation agencies; licensing and validation handled with language-service partners.
Study fit: sponsors and CROs that want a no-code eCOA build tool with eConsent and televisits on one platform
Medable pairs a large library (400+ validated instruments, 120+ locales) with Study Studio, a no-code builder its site says takes studies live in 4 to 6 weeks. It publishes Part 11, Annex 11, HIPAA and GDPR compliance but no regulatory approval counts or prices.
Validated instrument library and licensing
400+ pre-built, validated instruments in a reusable library with AI-assisted instrument generation; licensing services are not described on the pages checked.
States compliance with 21 CFR Part 11, Annex 11, HIPAA, GDPR and ICH GCP and says its eCOA data can support primary endpoints in pivotal studies; deployed in nearly 400 trials, with no approval counts published.
Study fit: CNS and other complex-endpoint trials that need clinician ratings, licensing support and global logistics
Signant combines a 50+ instrument library, in-house licensing support and 50+ clinical and eCOA experts with operations in 135+ countries. It says it supported 25% of FDA and EMA novel drug approvals from 2020 to 2025 and now adds wearable sensors through Ametris. Builds are vendor-led and prices are not published.
Validated instrument library and licensing
Library of 50+ instruments, many pre-approved by authors; scale licensing and management support; 50+ clinical and eCOA experts.
Study fit: sponsors that want eCOA, IRT and eConsent from one vendor across many languages
YPrime covers 250+ languages and 100+ countries and integrates eCOA with its own IRT and eConsent. It documents Part 11 and GxP compliance and nearly 1,000 studies, but no approval counts, and its ISO 27001 certification is still in progress. Builds are vendor-led and prices are not published.
Validated instrument library and licensing
Instrument licensing relationships and pre-validated eCOA libraries; library size and science team not published.
This guide compares 8 products across the same feature topics. Each statement describes what the available public sources document, including limitations and study requirements.
Scope: Electronic clinical outcome assessment (eCOA) platforms that capture patient-reported (ePRO), clinician-reported, observer-reported and performance outcomes in regulated clinical trials, as a sponsor, CRO or academic research team would shortlist them.
Validated instrument library and licensing
Regulatory compliance and track record
Global scale and languages
Capture modes and integrations
Time to launch and self-service build
Published pricing and terms
A vendor’s published claim is not independent confirmation that a product will meet your study’s needs. Check deployment, validation, integrations and commercial terms with the vendor.
Outside this comparison: Not included in this comparison: Suvoda, Datacubed Health and Clinical ink.
An eCOA (electronic clinical outcome assessment) platform captures patient-reported, clinician-reported, observer-reported and performance outcomes electronically in a clinical trial, on participants' own phones, provisioned devices, tablets at the site or the web, with time stamps and an audit trail.
Which eCOA platforms suit a large global pivotal trial?
On published scale, Medidata (200+ languages, 1,600+ eCOA studies), Clario (120+ countries, 100+ languages), Signant Health (135+ countries, 600+ live eCOA studies), YPrime (250+ languages, 100+ countries) and Kayentis (85 countries, 120 languages) all document global deployments. Medidata, Clario and Signant also publish company-wide figures on the share of FDA and EMA approvals their technology supported.
How long does an eCOA study take to set up?
Published figures vary: Medidata reports an average study start of 8 weeks, Medable 4 to 6 weeks with its no-code Study Studio, Castor 4 to 8 weeks for managed builds and weeks for self-service builds, and Clario as little as 2 weeks for its early-phase oncology package.
Can participants use their own phones (BYOD)?
The platforms here document participant-owned-device capture. Provisioned-device supply and management differ by vendor; check the feature notes and confirm the protocol’s device requirements.
How does eCOA differ from ePRO?
eCOA is electronic clinical outcome assessment, covering patient reports, clinician reports, observer reports and performance tasks. ePRO is the part reported directly by the participant. Check the vendor’s documented support for each assessment workflow.